Michael R. Bishop

6.6k total citations
155 papers, 2.8k citations indexed

About

Michael R. Bishop is a scholar working on Hematology, Oncology and Immunology. According to data from OpenAlex, Michael R. Bishop has authored 155 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 82 papers in Hematology, 78 papers in Oncology and 39 papers in Immunology. Recurrent topics in Michael R. Bishop's work include Hematopoietic Stem Cell Transplantation (57 papers), CAR-T cell therapy research (57 papers) and Acute Myeloid Leukemia Research (23 papers). Michael R. Bishop is often cited by papers focused on Hematopoietic Stem Cell Transplantation (57 papers), CAR-T cell therapy research (57 papers) and Acute Myeloid Leukemia Research (23 papers). Michael R. Bishop collaborates with scholars based in United States, Germany and Spain. Michael R. Bishop's co-authors include Sergio Giralt, Justin Kline, Wendy Stock, Andrew Artz, Koen van Besien, Richard A. Larson, Peter A. Riedell, Stephan A. Grupp, Lucy A. Godley and Hillard M. Lazarus and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Blood.

In The Last Decade

Michael R. Bishop

146 papers receiving 2.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael R. Bishop United States 25 1.3k 1.2k 707 534 396 155 2.8k
Sairah Ahmed United States 23 597 0.4× 1.4k 1.2× 517 0.7× 239 0.4× 484 1.2× 219 2.1k
Adrian Goycoolea 2 1.6k 1.2× 796 0.7× 556 0.8× 381 0.7× 209 0.5× 3 2.8k
Dirk Schwabe Germany 30 1.2k 0.9× 1.2k 1.0× 1.4k 2.0× 633 1.2× 164 0.4× 105 3.7k
Johanna Tischer Germany 28 1.8k 1.4× 969 0.8× 789 1.1× 703 1.3× 135 0.3× 121 2.6k
Ibrahim Aldoss United States 29 1.1k 0.8× 899 0.8× 251 0.4× 1.0k 2.0× 244 0.6× 190 2.5k
Wolfgang Bethge Germany 35 1.9k 1.4× 1.3k 1.1× 1.3k 1.9× 442 0.8× 373 0.9× 193 3.9k
Ricardo Spielberger United States 27 1.3k 1.0× 1.4k 1.2× 456 0.6× 497 0.9× 434 1.1× 84 3.5k
Iskra Pusic United States 22 1.7k 1.3× 452 0.4× 655 0.9× 357 0.7× 167 0.4× 77 2.5k
Aleksandr Lazaryan United States 21 678 0.5× 797 0.7× 443 0.6× 200 0.4× 275 0.7× 103 1.7k
Margaret O’Donnell United States 28 2.2k 1.6× 1.1k 0.9× 433 0.6× 884 1.7× 394 1.0× 91 3.4k

Countries citing papers authored by Michael R. Bishop

Since Specialization
Citations

This map shows the geographic impact of Michael R. Bishop's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael R. Bishop with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael R. Bishop more than expected).

Fields of papers citing papers by Michael R. Bishop

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael R. Bishop. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael R. Bishop. The network helps show where Michael R. Bishop may publish in the future.

Co-authorship network of co-authors of Michael R. Bishop

This figure shows the co-authorship network connecting the top 25 collaborators of Michael R. Bishop. A scholar is included among the top collaborators of Michael R. Bishop based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael R. Bishop. Michael R. Bishop is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cao, Guoshuai, Erting Tang, Jun Wan, et al.. (2025). Two-stage CD8+ CAR T-cell differentiation in patients with large B-cell lymphoma. Nature Communications. 16(1). 4205–4205. 2 indexed citations
2.
Roloff, Gregory W., Satyajit Kosuri, Adam DuVall, et al.. (2024). Expedited evaluation of hereditary hematopoietic malignancies in the setting of stem cell transplantation. Haematologica. 109(11). 3739–3744. 1 indexed citations
3.
Rojek, Alexandra E., Nausheen Ahmed, Sairah Ahmed, et al.. (2024). CAR T Cell Therapy in Early Relapsed/Refractory Large B-Cell Lymphoma: Real World Analysis from the Cell Therapy Consortium. Blood. 144(Supplement 1). 4503–4503.
4.
Bishop, Michael R.. (2024). Late complications and long-term care of adult CAR T-cell patients. Hematology. 2024(1). 109–115. 7 indexed citations
5.
Gong, He, Theodore Karrison, Wendy Stock, et al.. (2023). Eltrombopag Is a Safe and Effective Agent to Treat Thrombocytopenia after Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT). Transplantation and Cellular Therapy. 29(2). S142–S143.
6.
Saygin, Caner, Gregory W. Roloff, Christopher N Hahn, et al.. (2022). Allogeneic hematopoietic stem cell transplant outcomes in adults with inherited myeloid malignancies. Blood Advances. 7(4). 549–554. 23 indexed citations
7.
Rojek, Alexandra E., Justin Kline, Daniel Appelbaum, et al.. (2021). Impact of Pre-Treatment Whole-Body Metabolic Tumor Volume on Toxicities and Outcomes in Patients Treated with Anti-CD19 CAR T-Cell Therapy for Aggressive Large B-Cell NHL. Transplantation and Cellular Therapy. 27(3). S193–S194. 1 indexed citations
8.
Neelapu, Sattva S., Sherry Adkins, Stephen M. Ansell, et al.. (2020). Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma. Journal for ImmunoTherapy of Cancer. 8(2). e001235–e001235. 11 indexed citations
9.
10.
11.
Godley, Lucy A., Justin Kline, Richard A. Larson, et al.. (2017). Validation of Pre-Transplant Biomarker Measurement and Risk Score for Non-Relapse Mortality after Allogeneic Hematopoietic Cell Transplant (HCT). Blood. 130. 4558–4558. 1 indexed citations
12.
Hsu, Jingmei, Andrew Artz, Sebastian Mayer, et al.. (2017). Combined Haploidentical and Umbilical Cord Blood Allogeneic Stem Cell Transplantation for High-Risk Lymphoma and Chronic Lymphoblastic Leukemia. Biology of Blood and Marrow Transplantation. 24(2). 359–365. 15 indexed citations
13.
Keudell, Gottfried von, Cara A. Rosenbaum, Todd M. Zimmerman, et al.. (2014). Pilot Study of Regulatory T Cell Depletion In The Setting Of Autologous Stem Cell Transplantation For Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 14. S150–S152. 2 indexed citations
14.
Muffly, Lori, Masha Kocherginsky, Wendy Stock, et al.. (2014). Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients. Haematologica. 99(8). 1373–1379. 167 indexed citations
15.
Gress, Ronald E., Jeffrey S. Miller, Minoo Battiwalla, et al.. (2013). Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: Part I. Biology of Relapse after Transplantation. Biology of Blood and Marrow Transplantation. 19(11). 1537–1545. 22 indexed citations
16.
Luger, Selina M., Olle Ringdén, M-J Zhang, et al.. (2011). Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS. Bone Marrow Transplantation. 47(2). 203–211. 194 indexed citations
17.
Bishop, Michael R.. (2003). Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Metastatic Breast Cancer. Clinical Breast Cancer. 4(1). 39–45. 6 indexed citations
18.
Mata, John E., John D. Jackson, S. K. Joshi, et al.. (2000). Pharmacokinetics and In Vivo Effects of a Six-Base Phosphorothioate Oligodeoxynucleotide with Anticancer and Hematopoietic Activities in Swine. Journal of Hematotherapy & Stem Cell Research. 9(2). 205–214. 1 indexed citations
19.
Kottaridis, Panagiotis, Julie M. Vose, David C. Linch, et al.. (1998). Allogeneic transplantation following failure of autologous transplantation for lymphoma.. UCL Discovery (University College London). 3 indexed citations
20.
Kessinger, Anne, Michael R. Bishop, JR Anderson, et al.. (1995). Comparison of Subcutaneous and Intravenous Administration of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor for Peripheral Blood Stem Cell Mobilization. Journal of Hematotherapy. 4(2). 81–84. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sairah Ahmed Breakdown of academic impact, for papers by Adrian Goycoolea Breakdown of academic impact, for papers by Dirk Schwabe Breakdown of academic impact, for papers by Johanna Tischer Breakdown of academic impact, for papers by Ibrahim Aldoss Breakdown of academic impact, for papers by Wolfgang Bethge Breakdown of academic impact, for papers by Ricardo Spielberger Breakdown of academic impact, for papers by Iskra Pusic Breakdown of academic impact, for papers by Aleksandr Lazaryan Breakdown of academic impact, for papers by Margaret O’Donnell
Rankless by CCL
2026